Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE8B | O95263 | 2/20 | 0.57 |
| ▸ | MET | P08581 | 2/20 | 0.46 |
| ▸ | CNR2 | P34972 | 7/20 | 0.46 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 3/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | CCNE2 | O96020 | 1/20 | 0.44 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.44 |
| ▸ | CDK2 | P24941 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | TOP2A | P11388 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3392762 | 0.87 | PDE8B (0.63) | PDE8BMETCNR2ADORA3HPGD | |
| SCHEMBL14911943 | 0.85 | CNR2 (0.60) | PDE8BCNR2 | |
| SCHEMBL4928309 | 0.81 | ALDH1A1 (0.52) | PDE8BMETHPGDALDH1A1TP53 | |
| SCHEMBL1067412 | 0.80 | PDE8B (0.59) | PDE8BMETCNR2ADORA3HPGD | |
| SCHEMBL19743352 | 0.78 | CNR2 (0.48) | PDE8BCNR2ADORA3HPGDALDH1A1 | |
| SCHEMBL14974967 | 0.76 | CNR2 (0.75) | PDE8BCNR2ALDH1A1 | |
| SCHEMBL14974011 | 0.76 | CNR2 (0.77) | CNR2 | |
| SCHEMBL14974973 | 0.76 | CNR2 (0.75) | PDE8BCNR2ALDH1A1 | |
| SCHEMBL3821565 | 0.76 | YTHDC1 (0.57) | HPGDCCNE2CCNE1CDK2 | |
| SCHEMBL18614407 | 0.76 | PDE8B (0.51) | PDE8BMETCNR2HPGDALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3943497-A1 | TRIAZOLO[4,5-D]PYRIMIDINE DERIVATIVES AS CB2 RECEPTOR ANTAGONISTS | F. Hoffmann-La Roche AG (CH) | 2022-01-26 | — | — | EP | disclosed |
| EP-3483163-B1 | TRIAZOLO[4,5-D]PYRIMIDINE DERIVATIVES AS CB2 RECEPTOR ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2021-06-23 | — | — | EP | disclosed |
| EP-3483163-A2 | TRIAZOLO[4,5-D]PYRIMIDINE DERIVATIVES AS CB2 RECEPTOR ANTAGONISTS | F. Hoffmann-La Roche AG (CH) | 2019-05-15 | — | — | EP | disclosed |
| EP-3041843-B1 | TRIAZOLO[4,5-D]PYRIMIDINE DERIVATIVES AS CB2 RECEPTOR ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2019-01-02 | — | — | EP | disclosed |
| US-9593123-B2 | Triazolo[4,5-D]pyrimidine derivatives | HOFFMANN-LA ROCHE INC. (US) | 2017-03-14 | — | — | US | disclosed |
| EP-3041843-A1 | NOVEL TRIAZOLO[4,5-D]PYRIMIDINE DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2016-07-13 | — | — | EP | disclosed |
| US-20160168158-A1 | NOVEL TRIAZOLO[4,5-D]PYRIMIDINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2016-06-16 | — | — | US | disclosed |
| EP-2271630-B1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | NOVARTIS AG (CH) | 2016-03-23 | — | — | EP | disclosed |
| EP-2782915-B1 | [1,2,3]TRIAZOLO[4,5-d]PYRIMIDINE DERIVATIVES AS AGONISTS OF THE CANNABINOID RECEPTOR 2 AGONISTS | HOFFMANN LA ROCHE (CH) | 2015-09-30 | — | — | EP | disclosed |
| EP-2782915-B1 | [1,2,3]TRIAZOLO[4,5-d]PYRIMIDINE DERIVATIVES AS AGONISTS OF THE CANNABINOID RECEPTOR 2 AGONISTS | HOFFMANN LA ROCHE (CH) | 2015-09-30 | — | — | EP | disclosed |
| EP-2782915-A1 | [1, 2, 3]TRIAZOLO [4, 5 -D]PYRIMIDINE DERIVATIVES AS AGONISTS OF THE CANNABINOID RECEPTOR 2 AGONISTS | F.HOFFMANN-LA ROCHE AG (CH) | 2014-10-01 | — | — | EP | disclosed |
| US-8592432-B2 | Compounds and compositions as protein kinase inhibitors | NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) | 2013-11-26 | — | — | US | disclosed |
| US-20130137676-A1 | NOVEL [1,2,3]TRIAZOLO[4,5-D]PYRIMIDINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2013-05-30 | — | — | US | disclosed |
| US-20130137676-A1 | NOVEL [1,2,3]TRIAZOLO[4,5-D]PYRIMIDINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2013-05-30 | — | — | US | disclosed |
| US-20130137676-A1 | NOVEL [1,2,3]TRIAZOLO[4,5-D]PYRIMIDINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2013-05-30 | — | — | US | disclosed |
| WO-2013076182-A1 | [1, 2, 3]TRIAZOLO [4, 5 -D] PYRIMIDINE DERIVATIVES AS AGONISTS OF THE CANNABINOID RECEPTOR 2 AGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2013-05-30 | — | — | WO | disclosed |
| US-20110135668-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2011-06-09 | — | — | US | disclosed |
| US-20110135668-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2011-06-09 | — | — | US | disclosed |
| EP-2271630-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2011-01-12 | — | — | EP | disclosed |
| WO-2009126515-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2009-10-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110135668-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | ROS1, INSR, IGF1R | PDE8B 1616/4885MET 60/4885CNR2 1745/4885 |
| US-20130137676-A1 | NOVEL [1,2,3]TRIAZOLO[4,5-D]PYRIMIDINE DERIVATIVES | TYMS, TBXA2R, TYMP | PDE8B 1554/4885MET 4039/4885CNR2 135/4885 |
| US-20160168158-A1 | NOVEL TRIAZOLO[4,5-D]PYRIMIDINE DERIVATIVES | TYMS, TYMP, P2RX4 | PDE8B 1834/4885MET 3436/4885CNR2 285/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.